Serologic IgE Immune Responses Against Aspergillus fumigatus and Candida albicans in Patients With Cystic Fibrosis

CHEST Journal ◽  
2002 ◽  
Vol 121 (3) ◽  
pp. 782-788 ◽  
Author(s):  
Luis Máiz ◽  
Manuela Cuevas ◽  
Santiago Quirce ◽  
José F. Cañón ◽  
Adalberto Pacheco ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Candida Albicans ◽  
Immune Responses ◽  
Aspergillus Fumigatus

scholarly journals Effect of Aspergillus fumigatus and Candida albicans on pro-inflammatory response in cystic fibrosis epithelium

2011 ◽  
Vol 10 (6) ◽  
pp. 401-406 ◽  
Author(s):  
James A. Reihill ◽  
John E. Moore ◽  
J. Stuart Elborn ◽  
Madeleine Ennis
Keyword(s):  
Cystic Fibrosis ◽  
Candida Albicans ◽  
Inflammatory Response ◽  
Aspergillus Fumigatus

Serologic response to candida albicans and aspergillus fumigatus in cystic fibrosis

Infection ◽  
1987 ◽  
Vol 15 (4) ◽  
pp. 308-310 ◽  
Author(s):  
B. Przyklenk ◽  
A. Bauernfeind ◽  
G. Hörl ◽  
G. Emminger
Keyword(s):  
Cystic Fibrosis ◽  
Candida Albicans ◽  
Aspergillus Fumigatus ◽  
Serologic Response

Immune Responses to Aspergillus fumigatus and Pseudomonas aeruginosa Antigens in Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis

CHEST Journal ◽  
1994 ◽  
Vol 106 (2) ◽  
pp. 513-519 ◽  
Author(s):  
Pazhayannur S. Murali ◽  
Kishore Pathial ◽  
Ronald H. Saff ◽  
Mark L. Splaingard ◽  
Durgaprasadrao Atluru ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Pseudomonas Aeruginosa ◽  
Immune Responses ◽  
Aspergillus Fumigatus ◽  
Allergic Bronchopulmonary Aspergillosis

scholarly journals Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy

mSphere ◽  
2019 ◽  
Vol 4 (5) ◽  
Author(s):  
Suresh Ambati ◽  
Emma C. Ellis ◽  
Jianfeng Lin ◽  
Xiaorong Lin ◽  
Zachary A. Lewis ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Aspergillus Fumigatus ◽  
Effective Dose ◽  
Cryptococcus Neoformans ◽  
Amphotericin B ◽  
Antifungal Drugs ◽  
Extracellular Matrices ◽  
Content Type ◽  
Order Of Magnitude ◽  
Life Threatening

ABSTRACT Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus cause life-threatening candidiasis, cryptococcosis, and aspergillosis, resulting in several hundred thousand deaths annually. The patients at the greatest risk of developing these life-threatening invasive fungal infections have weakened immune systems. The vulnerable population is increasing due to rising numbers of immunocompromised individuals as a result of HIV infection or immunosuppressed individuals receiving anticancer therapies and/or stem cell or organ transplants. While patients are treated with antifungals such as amphotericin B, all antifungals have serious limitations due to lack of sufficient fungicidal effect and/or host toxicity. Even with treatment, 1-year survival rates are low. We explored methods of increasing drug effectiveness by designing fungicide-loaded liposomes specifically targeted to fungal cells. Most pathogenic fungi are encased in cell walls and exopolysaccharide matrices rich in mannans. Dectin-2 is a mammalian innate immune membrane receptor that binds as a dimer to mannans and signals fungal infection. We coated amphotericin-loaded liposomes with monomers of Dectin-2’s mannan-binding domain, sDectin-2. sDectin monomers were free to float in the lipid membrane and form dimers that bind mannan substrates. sDectin-2-coated liposomes bound orders of magnitude more efficiently to the extracellular matrices of several developmental stages of C. albicans, C. neoformans, and A. fumigatus than untargeted control liposomes. Dectin-2-coated amphotericin B-loaded liposomes reduced the growth and viability of all three species more than an order of magnitude more efficiently than untargeted control liposomes and dramatically decreased the effective dose. Future efforts focus on examining pan-antifungal targeted liposomal drugs in animal models of fungal diseases. IMPORTANCE Invasive fungal diseases caused by Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus have mortality rates ranging from 10 to 95%. Individual patient costs may exceed $100,000 in the United States. All antifungals in current use have serious limitations due to host toxicity and/or insufficient fungal cell killing that results in recurrent infections. Few new antifungal drugs have been introduced in the last 2 decades. Hence, there is a critical need for improved antifungal therapeutics. By targeting antifungal-loaded liposomes to α-mannans in the extracellular matrices secreted by these fungi, we dramatically reduced the effective dose of drug. Dectin-2-coated liposomes loaded with amphotericin B bound 50- to 150-fold more strongly to C. albicans, C. neoformans, and A. fumigatus than untargeted liposomes and killed these fungi more than an order of magnitude more efficiently. Targeting drug-loaded liposomes specifically to fungal cells has the potential to greatly enhance the efficacy of most antifungal drugs.

Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis

Mycoses ◽  
2003 ◽  
Vol 46 (1-2) ◽  
pp. 19-23 ◽  
Author(s):  
N. Bakare ◽  
V. Rickerts ◽  
J. Bargon ◽  
G. Just-Nübling
Keyword(s):  
Cystic Fibrosis ◽  
Aspergillus Fumigatus ◽  
Fungal Species ◽  
Adult Patients

scholarly journals Immune responses against Aspergillus fumigatus

2011 ◽  
Vol 24 (4) ◽  
pp. 315-322 ◽  
Author(s):  
Robert A. Cramer ◽  
Amariliz Rivera ◽  
Tobias M. Hohl
Keyword(s):  
Immune Responses ◽  
Aspergillus Fumigatus
Sign in / Sign up

Export Citation Format

Share Document